MKMaaike Kusters

Maaike Kusters

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maaike Kusters has a total of 314 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease

    by Valentina Guarnieri, Jesmeen Maimaris, Sohilla Lotfy, Elizabeth Rivers, Stuart Adams, Kimberly Gilmour, Andrea Meinhardt, Arnold Awuah, Mercedes Selby, Daisy Shillingford, et al.

    Data on late complications after hematopoietic stem cell transplantation (HSCT) in children with chronic granulomatous disease (CGD) are limited. We retrospectively analyzed 42 pediatric CGD patients who survived >2 years post-HSCT (1994–2020) at Great Ormond Street Hospital. X-linked CGD accounted for 69%. Pre-HSCT comorbidities included lung disease (48%), colitis/fistulizing disease (45%), and liver abscesses (19%). Median HSCT age was 6 years. 10-year overall survival was 95.2%, and event-free survival (events: death, second intervention) was 81%. 13 (33%) cases developed autoimmunity (AI); eight had relapsing or late-onset (>2 years) AI. Organ-specific late effects included lung abnormalities (n = 7), liver dysfunction (n = 7), renal disease (n = 3), and recurrent/new-onset colitis (n = 3). Endocrine sequelae comprised obesity (n = 15), gonadal dysfunction (n = 9), and short stature (n = 7). Skeletal (n = 6), neurological (n = 6), psychological (n = 19), visual (n = 5), and hearing impairments (n = 4) were noted. Late malignancy was reported in two cases. HSCT offers excellent long-term survival in CGD, but significant late effects underscore the need for extended multidisciplinary follow-up.

  • Open Access

    Dominant negative variants in ITPR3 impair T cell Ca2+ dynamics causing combined immunodeficiency

    by Elena Blanco, Carme Camps, Sameer Bahal, Mohit D. Kerai, Matteo P. Ferla, Adam M. Rochussen, Adam E. Handel, Zainab M. Golwala, Helena Spiridou Goncalves, Susanne Kricke, et al.

    The importance of calcium (Ca2+) as a second messenger in T cell signaling is exemplified by genetic deficiencies of STIM1 and ORAI1, which abolish store-operated Ca2+ entry (SOCE) resulting in combined immunodeficiency (CID). We report five unrelated patients with de novo missense variants in ITPR3, encoding a subunit of the inositol 1,4,5-trisphosphate receptor (IP3R), which forms a Ca2+ channel in the endoplasmic reticulum (ER) membrane responsible for the release of ER Ca2+ required to trigger SOCE, and for Ca2+ transfer to other organelles. The patients presented with CID, abnormal T cell Ca2+ homeostasis, incompletely penetrant ectodermal dysplasia, and multisystem disease. Their predominant T cell immunodeficiency is characterized by significant T cell lymphopenia, defects in late stages of thymic T cell development, and impaired function of peripheral T cells, including inadequate NF-κB- and NFAT-mediated, proliferative, and metabolic responses to activation. Pathogenicity is not due to haploinsufficiency, rather ITPR3 protein variants interfere with IP3R channel function leading to depletion of ER Ca2+ stores and blunted SOCE in T cells.


  • Open Access

    A corpus of GA4GH phenopackets: Case-level phenotyping for genomic diagnostics and discovery

    by Daniel Danis, Michael J. Bamshad, Yasemin Bridges, Andrés Caballero-Oteyza, Pilar Cacheiro, Leigh C. Carmody, Leonardo Chimirri, Jessica X. Chong, Ben Coleman, Raymond Dalgleish, et al.


  • Open Access

    A corpus of GA4GH Phenopackets: case-level phenotyping for genomic diagnostics and discovery

    by Daniel Danis, Michael J Bamshad, Yasemin Bridges, Pilar Cacheiro, Leigh C Carmody, Jessica X Chong, Ben Coleman, Raymond Dalgleish, Peter J Freeman, Adam S L Graefe, et al.

    Summary: The Global Alliance for Genomics and Health (GA4GH) Phenopacket Schema was released in 2022 and approved by ISO as a standard for sharing clinical and genomic information about an individual, including phenotypic descriptions, numerical measurements, genetic information, diagnoses, and treatments. A phenopacket can be used as an input file for software that supports phenotype-driven genomic diagnostics and for algorithms that facilitate patient classification and stratification for identifying new diseases and treatments. There has been a great need for a collection of phenopackets to test software pipelines and algorithms. Here, we present phenopacket-store. Version 0.1.12 of phenopacket-store includes 4916 phenopackets representing 277 Mendelian and chromosomal diseases associated with 236 genes, and 2872 unique pathogenic alleles curated from 605 different publications. This represents the first large-scale collection of case-level, standardized phenotypic information derived from case reports in the literature with detailed descriptions of the clinical data and will be useful for many purposes, including the development and testing of software for prioritizing genes and diseases in diagnostic genomics, machine learning analysis of clinical phenotype data, patient stratification, and genotype-phenotype correlations. This corpus also provides best-practice examples for curating literature-derived data using the GA4GH Phenopacket Schema.


  • JAK Inhibition in STAT1 Gain-of-Function–Mediated Treatment-Resistant Autoimmune Hepatitis

    by Nedim Hadžić, Maesha Deheragoda, Austen Worth, Sanjay Bansal, Marianne Samyn, Maaike Kusters


  • Top Cited Papers
    Open Access

    The Human Phenotype Ontology in 2024: phenotypes around the world

    by Michael A Gargano, Nicolas Matentzoglu, Ben Coleman, Eunice B Addo-Lartey, Anna V Anagnostopoulos, Joel Anderton, Paul Avillach, Anita M Bagley, Eduard Bakštein, James P Balhoff, et al.

    The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.


  • Open Access

    Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT

    by C. Schuetz, J. Gerke, M. Ege, J. Walter, M. Kusters, A. Worth, J. A. Kanakry, D. Dimitrova, B. Wolska-Kuśnierz, K. Chen, et al.

    Patients with hypomorphic mutations in the RAG1 or RAG2 gene present with either Omenn syndrome or atypical combined immunodeficiency with a wide phenotypic range. Hematopoietic stem cell transplantation (HSCT) is potentially curative, but data are scarce. We report on a worldwide cohort of 60 patients with hypomorphic RAG variants who underwent HSCT, 78% of whom experienced infections (29% active at HSCT), 72% had autoimmunity, and 18% had granulomas pretransplant. These complications are frequently associated with organ damage. Eight individuals (13%) were diagnosed by newborn screening or family history. HSCT was performed at a median of 3.4 years (range 0.3-42.9 years) from matched unrelated donors, matched sibling or matched family donors, or mismatched donors in 48%, 22%, and 30% of the patients, respectively. Grafts were T-cell depleted in 15 cases (25%). Overall survival at 1 and 4 years was 77.5% and 67.5% (median follow-up of 39 months). Infection was the main cause of death. In univariable analysis, active infection, organ damage pre-HSCT, T-cell depletion of the graft, and transplant from a mismatched family donor were predictive of worse outcome, whereas organ damage and T-cell depletion remained significant in multivariable analysis (hazard ratio [HR] = 6.01, HR = 8.46, respectively). All patients diagnosed by newborn screening or family history survived. Cumulative incidences of acute and chronic graft-versus-host disease were 35% and 22%, respectively. Cumulative incidences of new-onset autoimmunity was 15%. Immune reconstitution, particularly recovery of naïve CD4+ T cells, was faster and more robust in patients transplanted before 3.5 years of age, and without organ damage. These findings support the indication for early transplantation.


  • Clinical implications of immune‐mediated diseases in children with Down syndrome

    by Ruud H. J. Verstegen, Krystal J. J. Chang, Maaike A. A. Kusters

    Children with Down syndrome have changes in their innate and adaptive immunity, which contribute to increased rates of infections, autoimmune diseases, and haematological malignancies. While improved care for congenital heart disease has decreased mortality and morbidity, complications related to immune‐mediated diseases continue to limit the life expectancy in Down syndrome. Infectious diseases are common and have a significant effect on development, behaviour and quality of life. Infection frequency and severity are influenced by various anatomical and physiological alterations in addition to immunological changes in Down syndrome. Thus, prevention of respiratory tract infections requires a multifactorial approach. This could include additional active and/or passive immunizations, prophylactic antibiotics, immunoglobulin replacement and ear, nose and throat surgical interventions. Autoimmune conditions like coeliac disease, type I diabetes mellitus and thyroid disease are classically mentioned in the context of Down syndrome. However, autoinflammatory conditions are more prevalent as well. Screening for autoimmune diseases is required and immunosuppression has to be used with caution. Future studies should address optimal screening programmes for immune‐mediated diseases in individuals with Down syndrome, as well as the effect of immune modulation, to further decrease morbidity and mortality, and improve the quality of life of individuals with Down syndrome.


  • Functionality of the pneumococcal antibody response in down syndrome subjects

    by M.A.A. Kusters, N.C.C. Manders, B.A.W. de Jong, R.W.N.M. van Hout, G.T. Rijkers, E. de Vries


  • Influenza A/H1N1 Vaccination Response Is Inadequate in Down Syndrome Children When the Latest Cut-off Values Are Used

    by Maaike A. Kusters, Vinus L.A. Bok, W.E.A. Bolz, E.G.W. Huijskens, M.F. Peeters, Esther de Vries

    We determined the response of 48 Down syndrome children to 2 doses of influenza A/H1N1 vaccination. Ninety-two percent of the children reached the previously defined protective level (hemagglutination-inhibition titer ≥1:40), but only 27% of the children reached the level of ≥1:110 which was recently described to predict the conventional 50% clinical protection rate in children. Further studies, and potentially adaptations of the schedule, are needed.